@article {PUKOWNIK6009, author = {EWELINA PUKOWNIK and MALGORZATA KUBICKA and BEATA KURYLO-RAFINSKA and ROBERT DEBSKI and PRZEMYSLAW GALAZKA and KRZYSZTOF CZYZEWSKI and ANNA KRENSKA and NATALIA BARTOSZEWICZ and EWA DEMIDOWICZ and AGATA MARJA{\'N}SKA and MAGDALENA DZIEDZIC and MONIKA POGORZALA and MARIUSZ WYSOCKI and JAN STYCZYNSKI}, title = {Impact of CMV and EBV on Immune Recovery After Allogeneic Hematopoietic Cell Transplantation in Children}, volume = {38}, number = {10}, pages = {6009--6013}, year = {2018}, doi = {10.21873/anticanres.12950}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Immune recovery is a key factor in the management of patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study analyzed the factors contributing to immune reconstitution after allo-HSCT. Patients and Methods: Overall, 65 children with malignant or non-malignant diseases were included in multivariate analyses. Results: The following factors contributed to a faster immune recovery: peripheral blood as a stem cell source and reactivation of CMV infection for CD3+ and CD4+ lymphocyte subpopulations; reactivation of CMV infection for CD8+ subset; donor EBV-IgG+ and no EBV reactivation for CD19 lymphocytes; recipient age below 10 years and peripheral blood as a stem cell source for NK cells. For CD2 and CD4/CD8 ratio no factor was significant in multivariate analysis. Conclusion: Patients receiving a graft from an EBV-IgG-positive donor and not having early EBV post-transplant viremia show faster recovery of the B-cells, while patients with early CMV-DNA-emia have a better re-establishment of T-cell subsets.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/10/6009}, eprint = {https://ar.iiarjournals.org/content/38/10/6009.full.pdf}, journal = {Anticancer Research} }